Dr. Michael Lovell is the President of AcraPharm Consulting, Inc. a company that provides project management and technical consulting services in pharmaceutical product development. Previously, Dr. Lovell was the General Manager of BioDevelopment Laboratories, an operating unit of Genzyme Transgenics Corporation (GTC). Dr. Lovell managed a contract formulation development group that provided analytical methods development and validation, preformulation, formulation and dosage form stability (product development) services to the pharmaceutical industry. Prior to its purchase by GTC, Dr. Lovell was a Vice President and one of three Principals of BioDevelopment Laboratories, Inc., a former Division of Arthur D. Little, Inc. BioDevelopment Laboratories, Inc. provided product development and product safety assessment services to the pharmaceutical, chemical and medical device industries. His major interests are the development of new dosage forms for drug delivery to achieve specific goals such as taste- masking, sustained/controlled-release, and improved bioavailability. Additional interests are development of new dosage forms for parenteral, oral, and subcutaneous administration to human and veterinary subjects. Dr. Lovell has over twenty years experience in pharmaceutical product development and consulting. Prior to joining Arthur D. Little, Inc. he was a group leader in the Drug Delivery Systems Research Department of Abbott Laboratories. He held positions of research investigator and senior research scientist at G. D. Searle and Bristol-Myers, respectively. Dr. Lovell received his Ph.D. in Pharmaceutical Analysis from the College of Pharmacy , University of Florida and a B.S. in Pharmacy (Cum Laude) from the Massachusetts College of Pharmacy & Allied Health Sciences.